Daiichi Sankyo Quietly Grows While Other Pharmaceutical Firm...( The Company Discusses Increasing ...),Health

The Company Discusses Increasing New Jersey Life Sciences Jobs With

Congressman Rodney Frelinghuysen

PARSIPPANY, N.J., Oct. 1 /PRNewswire/ -- Daiichi Sankyo, Inc. has been steadily expanding its New Jersey facilities and rapidly increasing its staffing since 2002 to support a growing pipeline of medications for cardiovascular disease, diabetes, oncology and infection. Daiichi Sankyo is one of the few pharmaceutical companies experiencing steady and sustained growth, in a market that has seen most of its larger competitors forced to downsize and consolidate operations.

Although not well known in the U. S., Daiichi Sankyo is heading toward mid-sized company status. "Over the next three years, we expect to achieve a 60 percent growth in sales," President and CEO Joseph P. Pieroni states. The company, which started its commercial operations in the U.S. about ten years ago, today revealed its plans for future growth and the impact it hopes to have in creating additional life sciences positions in New Jersey at a meeting with Congressman Rodney Frelinghuysen (N.J. - 11th District). The Congressman was visiting Daiichi Sankyo's U.S. headquarters to personally meet with the management and employees to discuss health care programs and the future of health care and the industry in the state.

"We applaud Congressman Frelinghuysen's conviction that all Americans should have access to affordable, high-quality health care," said Pieroni. "We are also grateful for his tireless efforts to ensure drug access for all our senior citizens through the Medicare Prescription Drug Bill. In addition, he supported doubling the research budget for the National Institutes of Health. Hopefully, we can demonstrate our appreciation by continuing to do what we do best: bring innovative medicines to the American public."

Pieroni explained that he was proud of the company's longstanding legacy of discovering leading cardiovascular and anti-infe
'/>"/>